Introduction:

The global Next Generation Sequencing Services Market is poised for remarkable growth, with projections indicating a robust CAGR of 19.9% from 2023 to 2030. By the end of the forecast period, the market is anticipated to soar to an impressive $20.39 billion. This surge is attributed to a myriad of factors propelling the industry forward, such as the decreasing costs associated with sequencing procedures, the emergence and approval of innovative targeted therapies, and the escalating prevalence of cancer worldwide.

Read Full Blog – https://meticulousblog.org/top-10-companies-in-next-generation-sequencing-services-market/

Market Drivers:

Cost-Efficiency in Sequencing Procedures: The decreasing costs of sequencing procedures have been a key catalyst for the market's growth, making NGS services more accessible and attractive for a broader range of applications.
Advancements in Targeted Therapies: The continual development and approval of new targeted therapies have significantly contributed to the expanding applications of NGS services, driving demand across various clinical areas.
Rising Cancer Prevalence: The global surge in cancer cases has heightened the demand for precise diagnostic tools and treatments, positioning NGS services as a crucial player in the fight against cancer.
Strategic Partnerships: Partnerships between NGS service providers and pharmaceutical companies have created synergies, fostering innovation and expanding the market reach.
Technological Advancements: Constant innovation in Next Generation Sequencing technologies has been a pivotal factor in market growth, enhancing the efficiency and accuracy of sequencing procedures.
Market Challenges:

Alternative Technologies: The availability of alternative technologies poses a challenge to the NGS services market, requiring continuous innovation and differentiation to maintain a competitive edge.
Skills Gap: A shortage of skilled professionals for sample preparation and analysis hinders the seamless execution of NGS procedures, emphasizing the need for workforce development.


Low Chances of Positive Actionable Mutations: The low likelihood of identifying positive actionable mutations for precision medicine limits the market's growth potential in certain applications.
Opportunities for Growth:

Expanding Applications in Research: The increasing applications of NGS in cancer and agri-genomics research present significant growth opportunities for market players.
Advancements in Sequencing Data Analytics: Continuous improvements in sequencing data analytics enhance the value proposition of NGS services, opening doors to new applications and markets.
Market Challenges:

Regulatory Concerns: Regulatory and standardization concerns in diagnostic testing pose challenges for market stakeholders, necessitating a harmonized regulatory framework for NGS services.
Installation of In-House Facilities: Large hospitals and research institutes are increasingly installing in-house NGS facilities, posing a challenge to external service providers.
Ethical Issues in Prenatal Testing: Ethical concerns and costs related to non-invasive prenatal genetic testing present challenges that must be navigated to ensure sustained market growth.
Top 10 Companies in the Next Generation Sequencing Services Market:

Illumina, Inc. (U.S.)

Founded in 1998, Illumina is a California-based company providing sequencing and array-based solutions globally.

Offers NGS services through its Core Illumina segment, including whole-genome sequencing, genotyping, and NIPT.

Operates in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa.

Subsidiaries include Illumina GmbH (Germany), Illumina Australia Pty. Ltd (Australia), and Illumina UK, Ltd. (U.K.).

Eurofins Scientific S.E. (Luxembourg)

Founded in 1987, Eurofins operates globally, offering analytical testing services across Clinical Diagnostics, Environmental Testing, and more.

Provides NGS services through BioPharmaceutical Services and Clinical Diagnostics business areas.

Presence in over 60 countries with subsidiaries like Diatherix (U.S.) and Eurofins BioPharma Product Testing Australia Pty Ltd. (Australia).

Invitae Corporation (U.S.)

Established in 2010, Invitae is a biotech company providing genetic testing services and digital health solutions.

Offers genetic tests in areas such as hereditary cancer, precision oncology, and rare diseases.

Geographic presence in the U.S., U.K., Canada, India, Australia, Japan, and subsidiaries like ArcherDX, LLC (U.S.) and Invitae Netherlands, B.V. (Netherlands).

Foundation Medicine, Inc. (U.S.)

Founded in 2010, Foundation Medicine specializes in next-generation sequencing, genomic profiling, and immunohistochemistry.

Key assays include FoundationOneCDx and FoundationOne LiquidCDx, catering to cancer diagnosis and treatment.

A subsidiary of F. Hoffmann-La Roche AG (Switzerland), with a presence in the U.S., Brazil, Romania, and Germany.

Beijing Genomics Institute (China)

Established in 1999, BGI is a Chinese company providing genomic sequencing services globally.

Offers integrated genomic sequencing and proteomic solutions to pharmaceutical companies, healthcare providers, and more.

Offices in Denmark, the U.S., China, and Japan, with sequencing services primarily conducted on the DNBSEQ NGS platform.

DirectLabs, LLC. (U.S.)

Founded in 1993, DirectLabs offers direct access laboratory testing and a wide range of health and wellness blood chemistry tests.

Provides affordable direct-to-consumer laboratory testing services across the U.S., except in New Jersey, New York, and Rhode Island.

Novogene Co., Ltd. (China)

Established in 2011, Novogene operates as a genomics solution provider with expertise in NGS.

Genomic sequencing labs in the U.S., China, Singapore, and the U.K., providing NGS services globally.

Subsidiaries include NOVOGENE CO., LTD. Inc. (U.S.), Novogene (U.K.) Company Limited (U.K.), and Novogene Japan K.K. (Japan).

PerkinElmer, Inc. (U.S.)

Founded in 1937, PerkinElmer is a multinational company offering products, solutions, and services for the life sciences and diagnostics markets.

Operates in the NGS Services market through the Diagnostics business segment, offering testing in cytogenetics, molecular genetics, and more.

Manufacturing and R&D facilities located in the U.S., China, Japan, and Germany.

Macrogen, Inc. (South Korea)

Established in 1997, Macrogen is a South Korean biotechnology company offering products in precision medicine, NGS, clinical diagnostics, and more.

Provides a range of NGS services, including whole genome, exome, targeted, and single-cell multi-omics sequencing.

Subsidiaries include Macrogen Japan Corp. (Japan) and Psomagen, Inc. (U.S.).

QIAGEN N.V. (Netherlands)

Founded in 1984, QIAGEN provides sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research.

Offers NGS services through its custom laboratory and genomic services under the Genomics/NG

Download Sample Copy: https://www.meticulousresearch.com/download-sample-report/cp_id=5041

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research